| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K71781559 | CTRPv2 | pan-cancer | AAC | -0.023 | 0.5 |
| mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | -0.019 | 0.5 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.023 | 0.5 |
| mRNA | QL-VIII-58 | GDSC1000 | pan-cancer | AAC | -0.027 | 0.6 |
| mRNA | NG-25 | GDSC1000 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | JW-480 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.6 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | sotrastaurin | CTRPv2 | pan-cancer | AAC | -0.023 | 0.6 |
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | -0.062 | 0.6 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |